The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.

In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the ...

AstraZeneca announced that its lung cancer therapy TAGRISSO® (osimertinib), when used in combination with chemotherapy, ...

New long-term data from the Phase III FLAURA2 trial confirm that Tagrisso combined with chemotherapy delivers a significant overall survival benefit over monotherapy in patients with advanced ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

The trial's principal investigator Pasi Janne said the results support osimertinib "as standard of care" for EGFR-mutated cancer patients. Janne also noted that AstraZeneca's drug "did not impose any ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) with new long-term overall survival (OS) ...

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...